IDH1 and acute myeloid leukemia: Agents targeting mutations in IDH1 mutations, such as AG-120 and FT-2102, and IDH2, such as AG-221 have shown promise in clinical trials, effectively lowering 2-HG levels, inducing cellular differentiation, and demonstrating clinical efficacy in patients with relapsed or refractory AML [23].